Tim Wilsdon recently presented at an education forum at ISPOR Latin America, talking about the challenges that gene therapy poses for value assessment and considerations for the future.
For more information about the conference, click here.
CRA's RADAR Insights: Factors impacting GKV rebates for orphan drugs in Germany - Part 1
Germany’s AMNOG introduced in 2011 follows health technology assessments (HTAs) with reimbursement price negotiations and some exceptions for orphan drugs...